Joshi Alumkal

Joshi Alumkal
About Joshi Alumkal

In previous studies, Dr. Joshi Alumkal has shown that the LSD1 (Lysine-specific demethylase 1) protein is a driver of prostate cancer cell growth and survival and that LSD1 is upregulated in aggressive prostate cancers. Thus, LSD1 suppression might provide a unique opportunity to control prostate cancer progression. Dr. Alumkal’s work will clarify the LSD1 gene pathways that account for LSD1’s effects, and he will evaluate small molecule inhibitors of LSD1. His results will lead the way to Phase I clinical trials of LSD1 inhibitors in patients with metastatic castration-resistant prostate cancer-the lethal form of this disease.


The 2011 John F. Scarpa – PCF Young Investigator Award

Joshi Alumkal, MD

Oregon Health & Science University Knight Cancer Institute


Joe Gray, PhD and Tomasz Beer, MD